bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2013: M A M F J
2012: D N O S A J J M

 
  Other news for:
Acquired Immunodeficiency Syndrome
Vitamins
 Resources from HONselect
Multivitamins Won't Boost Standard HIV Care, Study Finds
Tanzanian trial found no better disease outcomes, and even hints at harm

By Robert Preidt

TUESDAY, Oct. 16 (HealthDay News) -- Taking high-dose multivitamin supplements did not cut the risk of HIV disease progression or death for Tanzanian patients already receiving standard medications aimed at suppressing the virus, a new study finds.

The daily supplements seemed tied to potentially harmful increased levels of a certain liver enzyme, according to a report published in the Oct. 17 issue of the Journal of the American Medical Association.

Over the past 15 years, the cocktail of medications known as highly active antiretroviral therapy (HAART) has greatly decreased HIV-related illness and death. Previous studies had also shown that high doses of multivitamins might reduce HIV-related illness and death in patients not receiving HAART, but the safety and effectiveness of combining the two regimens hadn't been determined.

In this new study, researchers compared the effects of high-dose multivitamin supplementation and standard-dose supplementation in Tanzanian HIV patients receiving HAART. The patients received daily capsules that contained either high or standard levels of vitamin B complex, vitamin C and vitamin E.

The study, however, was stopped early (after a median follow-up of 15 months) because there was evidence that patients taking the high-dose multivitamin supplement had unhealthily increased levels of the liver enzyme alanine transaminase.

At that point, there also was no difference in either disease progression or death risk for patients taking high- or normal-dose multivitamin supplementation, said researchers led by Sheila Isanaka of the Harvard School of Public Health, in Boston.

Further research is needed to learn how vitamin supplements can best be used with HAART to reduce HIV disease progression and death risk, the research team concluded.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about HIV treatment.

SOURCE: Journal of the American Medical Association, news release, Oct. 16, 2012

Copyright © 2012 HealthDay. All rights reserved. URL:http://www.healthscout.com/template.asp?id=669624

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Antiretroviral Therapy, Highly Active
Death
Disease Progression
Risk
Association
Liver
Research Personnel
Hypersensitivity
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact